Patents Assigned to Orbsen Therapeutics Limited
-
Patent number: 11952590Abstract: Stromal stem cells are prospectively isolated from human bone marrow then expanded into clonal populations and cultured and used, the isolation being on the basis of expression of a cell surface marker, wherein the cell surface marker binds an antibody and wherein said antibody cross reacts with a cell surface marker found on mouse stromal stem cells or rat stromal stem cells, and optionally also on a cell of at least one other mammalian species selected from mouse, rat, horse, rabbit and pig cells. Useful stromal stem cell populations are positive for SDC2.Type: GrantFiled: June 5, 2023Date of Patent: April 9, 2024Assignee: Orbsen Therapeutics LimitedInventor: Stephen J. Elliman
-
Patent number: 11952589Abstract: Stromal stem cells are prospectively isolated from human bone marrow then expanded into clonal populations and cultured and used, the isolation being on the basis of expression of a cell surface marker, wherein the cell surface marker binds an antibody and wherein said antibody cross reacts with a cell surface marker found on mouse stromal stem cells or rat stromal stem cells, and optionally also on a cell of at least one other mammalian species selected from mouse, rat, horse, rabbit and pig cells. Useful stromal stem cell populations are positive for SDC2.Type: GrantFiled: June 5, 2023Date of Patent: April 9, 2024Assignee: Orbsen Therapeutics LimitedInventor: Stephen J. Elliman
-
Patent number: 11926848Abstract: Stromal stem cells are prospectively isolated from human bone marrow then expanded into clonal populations and cultured and used, the isolation being on the basis of expression of a cell surface marker, wherein the cell surface marker binds an antibody and wherein said antibody cross reacts with a cell surface marker found on mouse stromal stem cells or rat stromal stem cells, and optionally also on a cell of at least one other mammalian species selected from mouse, rat, horse, rabbit and pig cells. Useful stromal stem cell populations are positive for SDC2.Type: GrantFiled: September 9, 2021Date of Patent: March 12, 2024Assignee: Orbsen Therapeutics LimitedInventor: Stephen J. Elliman
-
Patent number: 11918687Abstract: Disclosed herein are compositions comprising isolated exosomes, for instance exosomes wherein at least 20% of the exosomes comprise SDC2, methods of isolation, and methods of use.Type: GrantFiled: January 13, 2017Date of Patent: March 5, 2024Assignee: ORBSEN THERAPEUTICS LIMITEDInventors: Stephen J. Elliman, Jack Kavanaugh, Larry Couture
-
Patent number: 11903997Abstract: Modulators of syndecan-2, such as an antibody to syndecan-2 that cross-links syndecan-2 on the cell surface or a syndiecan-2 polypeptide that interferes with syndecan-2 receptor binding, is used to regulate a Th17 mediated disease such as an autoimmune disease, fibrosis or cancer.Type: GrantFiled: October 9, 2018Date of Patent: February 20, 2024Assignee: Orbsen Therapeutics LimitedInventors: Stephen J. Elliman, Laura Rose Barkley, Jack Kavanaugh
-
Patent number: 11884936Abstract: Stromal stem cells are prospectively isolated from human bone marrow then expanded into clonal populations and cultured and used, the isolation being on the basis of expression of a cell surface marker, wherein the cell surface marker binds an antibody and wherein said antibody cross reacts with a cell surface marker found on mouse stromal stem cells or rat stromal stem cells, and optionally also on a cell of at least one other mammalian species selected from mouse, rat, horse, rabbit and pig cells. Useful stromal stem cell populations are positive for SDC2.Type: GrantFiled: June 5, 2023Date of Patent: January 30, 2024Assignee: Orbsen Therapeutics LimitedInventor: Stephen J. Elliman
-
Patent number: 11434471Abstract: Stromal stem cells are prospectively isolated from human bone marrow then expanded into clonal populations and cultured and used, the isolation being on the basis of expression of a cell surface marker, wherein the cell surface marker binds an antibody and wherein said antibody cross reacts with a cell surface marker found on mouse stromal stem cells or rat stromal stem cells, and optionally also on a cell of at least one other mammalian species selected from mouse, rat, horse, rabbit and pig cells. Useful stromal stem cell populations are positive for SDC2.Type: GrantFiled: December 1, 2021Date of Patent: September 6, 2022Assignee: Orbsen Therapeutics LimitedInventor: Stephen Joseph Elliman
-
Patent number: 11268067Abstract: Disclosed herein are methods of isolating SDC2+ stromal stem cells by expression of surface marker CD39. Also disclosed herein are stromal stem cells isolated by said methods.Type: GrantFiled: July 12, 2018Date of Patent: March 8, 2022Assignee: ORBSEN THERAPEUTICS LIMITEDInventors: Stephen J. Elliman, Jack Kavanaugh, Larry A. Couture, Lisa O'Flynn
-
Patent number: 11230700Abstract: Stromal stem cells are prospectively isolated from human bone marrow then expanded into clonal populations and cultured and used, the isolation being on the basis of expression of a cell surface marker, wherein the cell surface marker binds an antibody and wherein said antibody cross reacts with a cell surface marker found on mouse stromal stem cells or rat stromal stem cells, and optionally also on a cell of at least one other mammalian species selected from mouse, rat, horse, rabbit and pig cells. Useful stromal stem cell populations are positive for SDC2.Type: GrantFiled: February 11, 2013Date of Patent: January 25, 2022Assignee: ORBSEN THERAPEUTICS LIMITEDInventor: Stephen Joseph Elliman
-
Patent number: 11142747Abstract: Stromal stem cells are prospectively isolated from human bone marrow then expanded into clonal populations and cultured and used, the isolation being on the basis of expression of a cell surface marker, wherein the cell surface marker binds an antibody and wherein said antibody cross reacts with a cell surface marker found on mouse stromal stem cells or rat stromal stem cells, and optionally also on a cell of at least one other mammalian species selected from mouse, rat, horse, rabbit and pig cells. Useful stromal stem cell populations are positive for SDC2.Type: GrantFiled: June 14, 2018Date of Patent: October 12, 2021Assignee: Orbsen Therapeutics LimitedInventor: Stephen J. Elliman
-
Patent number: 11026994Abstract: SDC2, compositions that comprise SDC2, vectors encoding SDC2 and compounds that modulate expression of SDC2 by cells are used for treatment of mammalian, e.g. human, cells to achieve immunomodulation or for other specific therapeutic interventions. Cells are treated by combining the cells with SDC2, treating the cells with an antibody or fragment thereof that binds SDC2 or modulating expression or activity of SDC2 by the cells. Cells or tissue are derived from treated cells for therapeutic uses based on their immunomodulatory or other therapeutic properties.Type: GrantFiled: January 22, 2019Date of Patent: June 8, 2021Assignee: ORBSEN THERAPEUTICS LIMITEDInventor: Stephen Joseph Elliman
-
Patent number: 10920197Abstract: Stromal stem cells are prospectively isolated from human bone marrow then expanded into clonal populations and cultured and used, the isolation being on the basis of expression of a cell surface marker, wherein the cell surface marker binds an antibody and wherein said antibody cross reacts with a cell surface marker found on mouse stromal stem cells or rat stromal stem cells, and optionally also on a cell of at least one other mammalian species selected from mouse, rat, horse, rabbit and pig cells. Useful stromal stem cell populations are positive for SDC2.Type: GrantFiled: September 5, 2019Date of Patent: February 16, 2021Assignee: Orbsen Therapeutics LimitedInventor: Stephen Joseph Elliman
-
Patent number: 10907131Abstract: Stromal stem cells are prospectively isolated from human bone marrow then expanded into clonal populations and cultured and used, the isolation being on the basis of expression of a cell surface marker, wherein the cell surface marker binds an antibody and wherein said antibody cross reacts with a cell surface marker found on mouse stromal stem cells or rat stromal stem cells, and optionally also on a cell of at least one other mammalian species selected from mouse, rat, horse, rabbit and pig cells. Useful stromal stem cell populations are positive for SDC2.Type: GrantFiled: April 1, 2016Date of Patent: February 2, 2021Assignee: Orbsen Therapeutics LimitedInventor: Stephen Joseph Elliman
-
Patent number: 10251934Abstract: SDC2, compositions that comprise SDC2, vectors encoding SDC2 and compounds that modulate expression of SDC2 by cells are used for treatment of mammalian, e.g. human, cells to achieve immunomodulation or for other specific therapeutic interventions. Cells are treated by combining the cells with SDC2, treating the cells with an antibody or fragment thereof that binds SDC2 or modulating expression or activity of SDC2 by the cells. Cells or tissue are derived from treated cells for therapeutic uses based on their immunomodulatory or other therapeutic properties.Type: GrantFiled: April 16, 2014Date of Patent: April 9, 2019Assignee: Orbsen Therapeutics LimitedInventor: Stephen Joseph Elliman
-
Patent number: 10124038Abstract: Modulators of syndecan-2, such as an antibody to syndecan-2 that cross-links syndecan-2 on the cell surface or a syndecan-2 polypeptide that interferes with syndecan-2 receptor binding, is used to regulate a Th17 mediated disease such as an autoimmune disease, fibrosis or cancer.Type: GrantFiled: March 18, 2016Date of Patent: November 13, 2018Assignee: ORBSEN THERAPEUTICS LIMITEDInventors: Stephen J. Elliman, Laura Rose Barkley, Jack Kavanaugh
-
Publication number: 20160058832Abstract: SDC2, compositions that comprise SDC2, vectors encoding SDC2 and compounds that modulate expression of SDC2 by cells are used for treatment of mammalian, e.g. human, cells to achieve immunomodulation or for other specific therapeutic interventions. Cells are treated by combining the cells with SDC2, treating the cells with an antibody or fragment thereof that binds SDC2 or modulating expression or activity of SDC2 by the cells. Cells or tissue are derived from treated cells for therapeutic uses based on their immunomodulatory or other therapeutic properties.Type: ApplicationFiled: April 16, 2014Publication date: March 3, 2016Applicant: Orbsen Therapeutics LimitedInventor: Stephen Joseph ELLIMAN
-
Publication number: 20150037292Abstract: Stromal stem cells are prospectively isolated from human bone marrow then expanded into clonal populations and cultured and used, the isolation being on the basis of expression of a cell surface marker, wherein the cell surface marker binds an antibody and wherein said antibody cross reacts with a cell surface marker found on mouse stromal stem cells or rat stromal stem cells, and optionally also on a cell of at least one other mammalian species selected from mouse, rat, horse, rabbit and pig cells. Useful stromal stem cell populations are positive for SDC2.Type: ApplicationFiled: February 11, 2013Publication date: February 5, 2015Applicant: Orbsen Therapeutics LimitedInventor: Stephen Joseph Elliman